I was disheartened to learn last week that the US Federal Drug Administration approved flibanserin for treatment of low female sexual desire. The decision was claimed as a victory for women. But as a researcher working in sexual dysfunction and interested in the medicalisation of sex, the victory tasted a little bitter.

Recent positive results from the Guinea Ebola vaccine trial, which suggested a vaccine could provide high protection against the virus, were welcome news. However, it’s also essential that we continue to carry out research to ensure Ebola patients are receiving appropriate care and effective treatment.